Results 141 to 150 of about 3,081 (193)

Bruton's tyrosine kinase inhibitors in diffuse large B-cell lymphoma therapy: critical considerations and future innovations. [PDF]

J Transl Med
Lu C, Chen Q, Shen Y, Chen M, Xie Y, Wang C, Yu L.   +6 more
europepmc   +1 more source

Estimated cardiac deaths associated with treating chronic lymphocytic leukemia with ibrutinib versus zanubrutinib in the United States. [PDF]

Future Oncol
Brown JR, Munir T, Lipsky AH, Challagulla S, Campbell D, Yang K, Fu Q, Aldairy W, Williams R, Tam CS.   +9 more
europepmc   +1 more source

Australasian chronic lymphocytic leukaemia consensus statement: 2026 update. [PDF]

Intern Med J
McKeague S, Czerwinski JK, Badoux X, Bennett R, Best G, Chia N, Cochrane T, Crassini K, Cull G, Di Ciaccio P, Fedele P, Harrup R, Jackson S, Kuss B, Lasica M, Lee D, Lew T, Marlton P, Menzies Wojtowicz M, Opat S, Ratnasingam S, Seymour JF, Talaulikar D, Tam CSL, Weinkove R, Wight J, Mulligan S, Anderson MA.   +27 more
europepmc   +1 more source

Where next for BTKi-BCL2i combinations in mantle cell lymphoma? [PDF]

Br J Haematol
Eyre TA.
europepmc   +1 more source

BTKi orelabrutinib improved the outcome of newly-diagnosed PCNS-LBCL by alleviating MyD88^L265P-induced PIM1 stability. [PDF]

J Hematol Oncol
Yuan Y, Dai B, Zhong H, Zheng J, Fan Z, Chen D, Wang Q, Wu H, Li Y, Zhu P, Ding T, Wang S, Wu K, Zhang Y, Wang Z, Feng R, Zhu F, Zheng K, Qin Z, Yang B, Chen H, Lin X, Yao Y, Zhuang D, Shi Z, Mao Y, Chen T.   +26 more
europepmc   +1 more source

Docirbrutinib is a pan-mutant BTK inhibitor and inhibits B-cell receptor signaling in chronic lymphocytic leukemia cells in preclinical and early clinical investigations. [PDF]

Blood Cancer J
Timofeeva N, Herrera B, Fujiwara H, Asami T, Endo H, Hatakeyama M, Nakajima F, Ohmoto H, Nishioka Y, Miyamoto K, Arimura A, Tantawy SI, Pinilla-Ibarz J, Coombs CC, Jain N, Sawa M, Gandhi V.   +16 more
europepmc   +1 more source

Evolving therapeutic strategies in mantle cell lymphoma: advancements and future directions. [PDF]

Leukemia
Tavarozzi R, Maher N, Catania G, Zacchi G, D'Andrea F, Sofia A, Zanni M, Ladetto M.   +7 more
europepmc   +1 more source

Chronic Lymphocytic Leukemia: Molecular Pathologies and Therapeutic Strategies. [PDF]

Int J Mol Sci
Meza K, Barrientos Risso C, Shah A, Romagnoli C, Sandoval J, Brauchle Y, Lyubimova A, Santos L, Goya Balaguer E, Barrientos J.   +9 more
europepmc   +1 more source

Surrogate Endpoints in CLL: From Promise and Pitfalls to a Context-Specific Validation Framework. [PDF]

Hematol Rep
Molica S.
europepmc   +1 more source

Hypertension and incident cardiovascular events after next-generation BTKi therapy initiation

Journal of Hematology and Oncology, 2022
Abstract Background Post-market analyses revealed unanticipated links between first-generation Bruton’s tyrosine kinase inhibitor (BTKi) therapy, ibrutinib, and profound early hypertension. Yet, whether this is seen with novel selective second (next)-generation BTKi therapy, acalabrutinib, is unknown.
Kerry Rogers, John C. Byrd, Daniel Addison   +2 more
exaly   +5 more sources